Did you know?
ChinaBio® Group is an investment, consulting and media firm helping western life science companies achieve success in China. ChinaBio works with U.S., European and APAC companies seeking partnerships, acquisitions, novel technologies and funding in China.  

>> Learn more…

Site Search

>> Advanced Search

  Quick Search:

Free Newsletter

  Email address:

Simcere to Develop Cancer Drug from OSI Pharma in China

publication date: Oct 20, 2009
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.

Simcere Pharmaceutical Group (先声药业) has acquired the China rights to a dual-mechanism cancer drug from OSI Pharmaceuticals. Simcere must first obtain regulatory approval for OSI-930, and then it will produce and market the drug in China. In the US, OSI-930 has completed a Phase I trial. Terms of the agreement were not disclosed. More details...

Stock Symbols: (NYSE: SCR) (NSDQ: OSIP)

Sorry... this feature or article is only available to subscribers.

>> Learn more about our subscription plans...

>> Free email newsletter...

>> Login...



ChinaBio® Events
Suzhou, China
May 18 - 19, 2016
Record attendance of 1008!
See us next year in Shunde!

>> More events...

Other Events
Hong Kong, China
June 15–17, 2016
Our Partners
Annual Sponsors
Official Partners
Supporting Partners
Media Sponsors